Rationale for the coadministration of albendazole and ivermectin to humans for malaria parasite transmission control

• Main Authors: Kevin C. Kobylinski, Haoues Alout, Brian D. Foy, Archie Clements, Poom Adisakwattana, Brett E. Swierczewski, Jason H. Richardson
• Other Authors: Armed Forces Research Institute of Medical Sciences, Thailand
• Format: Review
• Published: 2018
• Subjects: Immunology and Microbiology; Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/34101
• Institution: Mahidol University

Copyright © 2014 by The American Society of Tropical Medicine and Hygiene. Recently there have been calls for the eradication of malaria and the elimination of soil-transmitted helminths (STHs). Malaria and STHs overlap in distribution, and STH infections are associated with increased risk for malaria. Indeed, there is evidence that suggests that STH infection may facilitate malaria transmission. Malaria and STH coinfection may exacerbate anemia, especially in pregnant women, leading to worsened child development and more adverse pregnancy outcomes than these diseases would cause on their own. Ivermectin mass drug administration (MDA) to humans for malaria parasite transmission suppression is being investigated as a potential malaria elimination tool. Adding albendazole to ivermectin MDAs would maximize effects against STHs. A proactive, integrated control platform that targets malaria and STHs would be extremely cost-effective and simultaneously reduce human suffering caused by multiple diseases. This paper outlines the benefits of adding albendazole to ivermectin MDAs for malaria parasite transmission suppression.